CN105264084A - 静默egfr表达的脱氧核糖核酸酶 - Google Patents

静默egfr表达的脱氧核糖核酸酶 Download PDF

Info

Publication number
CN105264084A
CN105264084A CN201480004837.1A CN201480004837A CN105264084A CN 105264084 A CN105264084 A CN 105264084A CN 201480004837 A CN201480004837 A CN 201480004837A CN 105264084 A CN105264084 A CN 105264084A
Authority
CN
China
Prior art keywords
oligonucleotide
egfr
sequence
modification sequence
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480004837.1A
Other languages
English (en)
Chinese (zh)
Inventor
杨泮池
赖薇云
白果能
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of CN105264084A publication Critical patent/CN105264084A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Saccharide Compounds (AREA)
CN201480004837.1A 2013-01-14 2014-01-14 静默egfr表达的脱氧核糖核酸酶 Pending CN105264084A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361752117P 2013-01-14 2013-01-14
US61/752,117 2013-01-14
PCT/US2014/011496 WO2014110577A1 (en) 2013-01-14 2014-01-14 Dnazyme for silencing the expression of egfr

Publications (1)

Publication Number Publication Date
CN105264084A true CN105264084A (zh) 2016-01-20

Family

ID=51167450

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480004837.1A Pending CN105264084A (zh) 2013-01-14 2014-01-14 静默egfr表达的脱氧核糖核酸酶

Country Status (7)

Country Link
US (1) US9856480B2 (enExample)
EP (1) EP2943578B1 (enExample)
JP (1) JP6574136B2 (enExample)
KR (1) KR20150136588A (enExample)
CN (1) CN105264084A (enExample)
CA (1) CA2898200A1 (enExample)
WO (1) WO2014110577A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116286831A (zh) * 2023-01-29 2023-06-23 珠海市人民医院 靶向egfr t790m突变体的核酸适配体及其在制备治疗肺癌药物中的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220061311A1 (en) * 2018-11-05 2022-03-03 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for reducing cryopreservation toxicity
IL302594A (en) * 2020-11-09 2023-07-01 1E Therapeutics Ltd Catalytic sequence based methods of treating or preventing bacterial infections

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004038019A2 (en) * 2002-10-23 2004-05-06 Isis Innovation Limited Dnazyme cleaving mutant polynucleotides
WO2012043633A1 (ja) * 2010-09-30 2012-04-05 独立行政法人国立精神・神経医療研究センター 優性変異遺伝子発現抑制剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US7365185B2 (en) * 2000-07-19 2008-04-29 Monsanto Technology Llc Genomic plant sequences and uses thereof
AU3497701A (en) * 2000-02-08 2001-08-20 Ribozyme Pharmaceuticals, Inc. Nucleozymes with endonuclease activity
EP1767632A3 (en) * 2001-05-29 2009-12-30 Sirna Therpeutics, Inc. A method for local administration of synthetic double-stranded oligonucleotides targeting a VEGF receptor
US6890719B2 (en) * 2002-05-10 2005-05-10 The Board Of Trustess Of The University Of Illinois Fluorescence based biosensor
WO2005108570A1 (ja) * 2004-05-11 2005-11-17 National University Corporation Yokohama National University 核酸酵素複合体
EP1766068A4 (en) * 2004-06-04 2010-03-03 Genentech Inc EGFR Mutations
BRPI0607235A2 (pt) * 2005-02-24 2009-08-25 Amgen Inc mutações do receptor do fator de crescimento epidérmico
CA2683559C (en) 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004038019A2 (en) * 2002-10-23 2004-05-06 Isis Innovation Limited Dnazyme cleaving mutant polynucleotides
WO2012043633A1 (ja) * 2010-09-30 2012-04-05 独立行政法人国立精神・神経医療研究センター 優性変異遺伝子発現抑制剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CRISPIN R. DASS等: "DNAzyme technology and cancer therapy- cleave and let die", 《MOLECULAR CANCER THERAPEUTICS》 *
GANG CHEN等: "Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 *
SCOTT K. SILVERMAN: "Catalytic DNA (deoxyribozymes) for synthetic applications-current abilities and future prospects", 《CHEMCOMM》 *
居乃琥: "《酶工程手册》", 31 August 2011, 中国轻工业出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116286831A (zh) * 2023-01-29 2023-06-23 珠海市人民医院 靶向egfr t790m突变体的核酸适配体及其在制备治疗肺癌药物中的应用
CN116286831B (zh) * 2023-01-29 2024-02-20 珠海市人民医院 靶向egfr t790m突变体的核酸适配体及其在制备治疗肺癌药物中的应用

Also Published As

Publication number Publication date
EP2943578A4 (en) 2017-01-25
WO2014110577A8 (en) 2015-10-08
WO2014110577A1 (en) 2014-07-17
CA2898200A1 (en) 2014-07-17
EP2943578B1 (en) 2019-04-10
JP6574136B2 (ja) 2019-09-18
KR20150136588A (ko) 2015-12-07
US9856480B2 (en) 2018-01-02
JP2016504046A (ja) 2016-02-12
US20160145625A1 (en) 2016-05-26
EP2943578A1 (en) 2015-11-18

Similar Documents

Publication Publication Date Title
EP3458474B1 (en) Combinations of mrnas encoding immune modulating polypeptides and uses thereof
US7858592B2 (en) Interfering RNAs against the promoter region of P53
JP6688292B2 (ja) 乳酸デヒドロゲナーゼ及びその薬剤の治療的阻害
JP6681422B2 (ja) リポタンパク質リパーゼ欠損（ｌｐｌｄ）集団におけるアポリポタンパク質ｃ−ｉｉｉ（ａｐｏｃｉｉｉ）発現の調節
JP2023536974A (ja) Ｌｐａ発現を阻害するための組成物及び方法
JP2021074010A (ja) Ｔｍｐｒｓｓ６発現を調節するための化合物及び方法
JP2021521796A (ja) 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド
US20180153919A1 (en) Organic compositions to treat kras-related diseases
EA022207B1 (ru) Антисмысловые олигонуклеотиды против фактора роста соединительной ткани и способы их применения
WO2023051822A1 (zh) 用于治疗与pcsk9相关疾病的靶向寡核苷酸
WO2025054270A1 (en) Compositions and methods for treating cancer
JP2025511859A (ja) 血液細胞分化に関連する臨床的に有意な徴候及び症状を有する対象を治療する方法
CN105264084A (zh) 静默egfr表达的脱氧核糖核酸酶
WO2009143371A2 (en) COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF
TWI580783B (zh) 用於靜默ｅｇｆｒ表現之去氧核糖核酸酶（ｄｎａｚｙｍｅ）
EP3936136A1 (en) Specific sirna molecules, composition and use thereof for the treatment of triple negative breast cancer
WO2009143372A2 (en) Compositions comprising a-raf, b-raf, and c-raf sirna and methods of use thereof
WO2009143281A2 (en) Compositions comprising c-met sirna and methods of use thereof
WO2026025099A1 (en) Compositions and methods for inhibiting dnmt1 methylation activity for reducing chemotherapy induced amplification and rearrangement in mixed lineage leukemia (mll)
WO2025199539A2 (en) Compositions for demethylation of bard1 and methods of use thereof for treating cancer
WO2024076781A1 (en) Polynucleotides for silencing transcript variant 1 of assembly factor for spindle microtubules and applications thereof
WO2009152346A2 (en) Compositions comprising phosphoinositide 3-kinase sirna and methods of use thereof
HK40102681A (zh) 用於治疗血管紧张素原(agt)相关病症的方法和组合物
EP3843845A1 (en) Inhibition of protein kinases to treat friedreich ataxia
HK40004825B (en) Combinations of mrnas encoding immune modulating polypeptides and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20200922

AD01 Patent right deemed abandoned